

Food and Drug Administration Rockville MD 20857

July 25, 2001

Mr. William Stahovec Manager, Regulatory Affairs Aspire Pharmaceuticals, Inc. 4011 SW 47th Avenue Suite 1107 Fort Lauderdale, FL 33314

Dear Mr. Stahovec:

Your petition requesting the Food and Drug Administration to determine as to whether a product was withdrawn from sale in the United Sates for reasons other than safety or effectiveness was received by this office on 07/25/01. It was assigned docket number 01P-0315/CP 1 and it was filed on 07/24/01. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Helen K. Harris

Dockets Management Branch

telen K. Tharris

011-0315

ACKI